PharmaVentures to Sell Former AstraZeneca Manufacturing Plant in UK

OXFORD, England, Feb. 25, 2019 /PRNewswire/ -- PharmaVentures Limited is pleased to announce that it has been appointed to sell a former AstraZeneca manufacturing site in Avonmouth, near Bristol, England. The API plant was bought in 2016 by Avara Pharma Services who, as part of the deal, took over the drug substance manufacture of the high-cholesterol drug Crestor for AstraZeneca on a contract basis. Restructuring of the Avara group has resulted in the current decision to put the Avlon facility into Administration.

Dr. Fintan Walton, Chief Executive of PharmaVentures, said: "We have had considerable experience in the divestment of manufacturing plants in the US and Europe and we are delighted to be given an opportunity to find a buyer for the Avlon plant as it represents an opportunity for a pharmaceutical manufacturer keen to expand its operations quickly into the UK."

About PharmaVentures

PharmaVentures is a premier transaction advisory firm; a world leader in partnering, pharma M&A deals and strategic alliances. With an unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes PharmaVentures uniquely placed to support healthcare businesses in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partner or buyer interest.

PharmaVentures Capital Limited is a wholly owned subsidiary of PharmaVentures Limited. All regulated activities are delivered through PharmaVentures Capital Limited, which is authorised and regulated by the Financial Conduct Authority (741356). PharmaVentures Capital Limited undertakes regulated activities for and on behalf of professional clients only as defined in the FCA handbook COBS 3.5.

Securities offered in the United States through Crito Capital LLC, member FINRA, SIPC and MSRB.

Find out more www.pharmaventures.com

PharmaVentures is based in Oxford, UK, employs over 20 professionals and has associates in N. America, Latin America, Asia-Pacific.

For further information, contact: Dr Fintan Walton, CEO, PharmaVentures Limited. Tel: +44-1865-332700, Email: enquiries@pharmaventures.com

SOURCE PharmaVentures Limited